Nuclear Medicine or Radiopharmaceuticals Market Size Was Valued at USD 6.13 Billion in 2022, and is Projected to Reach USD 11.0 Billion by 2030, Growing at a CAGR of 7.6% From 2023-2030.
Nuclear Medicine Or Radiopharmaceuticals Market is a specialized field within the medical domain that utilizes small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and treat diseases. Radiopharmaceuticals are compounds consisting of a radioactive substance (radionuclide) combined with a pharmaceutical agent. These substances emit gamma rays that can be detected by specialized cameras or scanners, allowing physicians to visualize and assess the functioning of organs or tissues within the body. in diagnostic procedures, radiopharmaceuticals are administered to patients orally, intravenously, or through inhalation. These compounds accumulate in specific organs or tissues, highlighting areas of abnormality or disease, and enabling doctors to diagnose conditions such as cancer, heart disease, or neurological disorders. Moreover, nuclear medicine is also employed in treatments, such as targeted radiation therapy for certain cancers. Radiopharmaceuticals used in therapy deliver radiation directly to the affected area, minimizing damage to surrounding healthy tissues.
“Customize Your Solution That Fit Within the Constraints of Your Annual Budget.!”
Request a Free Sample of the Nuclear Medicine Or Radiopharmaceuticals Market Report:
https://introspectivemarketresearch.com/request/15924
Top Company Profiles Included in Nuclear Medicine Or Radiopharmaceuticals Market:
Actinium Pharmaceuticals Inc. (U.S.), Alliance Medical (U.K.), Avid Bioservices Inc(U.S.), Bayer Healthcare Pharmaceuticals (Germany), Bracco Diagnostics Inc. (Italy), Cardinal Health Inc. (U.S.), Ge Healthcare (U.S.), Ion Beam Applications S.A (Belgium), Jubilant Pharma (India), Lantheus Medical Imaging Inc. (U.S.), Medi-Radiopharma Ltd (Hungary), Nordion Inc. (Canada), Novartis/Advanced Accelerator Applications (France), Positron Corporation (U.S.), Radiopharm Theranostics Ltd. (U.S.), Curium (France), Eli Lilly And Company (U.S.), Fujifilm Toyama Chemical Co., Ltd. (Japan)
The report Nuclear Medicine Or Radiopharmaceuticals Market report provides an in-depth analysis of the Nuclear Medicine Or Radiopharmaceuticals Market including a detailed description of market growth and size, value, and the key opportunities in the market, as well as an outline of the factors that are and will be driving the industry's growth, taking previous growth patterns into account. The global Nuclear Medicine Or Radiopharmaceuticals Market Report provides an in-depth analysis of the market state of Nuclear Medicine Or Radiopharmaceuticals Market manufacturers, including the latest facts and data, SWOT analysis, and expert views from around the world. The cost structure, market size, Nuclear Medicine Or Radiopharmaceuticals market sales, Gross Margin and Market Share, Price, Revenue, Size, Forecast, and Growth Rate are all calculated in the report. The income earned from the sale of This Study and technologies by various application industries is considered in the report.
Segmentation Analysis of Nuclear Medicine Or Radiopharmaceuticals Market :
The Nuclear Medicine Or Radiopharmaceuticals market can be segmented in various ways to better understand and cater to the diverse needs and preferences of consumers. Here are some common segmentation criteria for the Nuclear Medicine Or Radiopharmaceuticals Market:
· Diagnostic
· Therapeutic
By Modality
· Single-photon emission Computed Tomography (SPECT)
· Positron Emission Tomography (PET)
· Alpha Emitters
· Beta Emitters
· Brachytherapy
By Application
· Oncology
· Cardiology
· Neurology
By End User
· Hospitals
· Specialty Clinics
Diagnostic Centers Market Share Data Market Segment by Regions and Countries Level Analysis:
§ North America (U.S., Canada, Mexico)
§ Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
§ Western Europe (Germany, U.K., France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
§ Asia-Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
§ Middle East & Africa (Turkey, Saudi Arabia, Bahrain, Kuwait, Qatar, UAE, Israel, South Africa)
§ South America (Brazil, Argentina, Rest of SA)
If You Have Any Queries Nuclear Medicine Or Radiopharmaceuticals Market Report, Visit:
https://introspectivemarketresearch.com/inquiry/15924
Key Industry Developments in the Nuclear Medicine or Radiopharmaceuticals Market:
· In March 2023, the International Atomic Energy Agency (IAEA) inked a pact with an 11-member consortium comprising Japanese universities and scientific institutions. This collaboration falls under the Rays of Hope initiative, aimed at fortifying the nuclear medicine workforce across Asia and the Pacific region.
· In January 2023, NorthStar Medical Radioisotopes, a notable American pharmaceutical company, embarked on a strategic alliance with Inhibrx, Inc. The primary aim of this collaboration is the co-development and production of innovative radiopharmaceuticals meticulously crafted to combat cancer. Radiopharmaceuticals assume a pivotal role within the domain of medical imaging, serving the dual purpose of diagnosing and treating cancer, making this partnership a significant step in advancing cancer care.
· In December 2022, Polarean Imaging Plc, a distinguished player in the medical imaging technology sector, achieved a momentous milestone by securing approval from the U.S. Food and Drug Administration (FDA) for Xenoview. This groundbreaking diagnostic radiopharmaceutical, intended for utilization alongside magnetic resonance imaging, is specifically tailored for evaluating lung ventilation in a broad spectrum of patients, encompassing both pediatric and adult populations.
· In March 2022, pharmaceutical giant Novartis announced a momentous achievement – the FDA's approval of Pluvicto. This groundbreaking drug is slated for treating adults grappling with an advanced form of cancer known as prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).
Our Free Sample Report Includes in Nuclear Medicine Or Radiopharmaceuticals Market:
· 2022 Updated Report Introduction, Overview, and In-depth industry analysis
· 50+ Pages Research Report (Inclusion of Updated Research)
· Provide Chapter-wise guidance on the Request
· 2022 Updated Regional Analysis with Graphical Representation of Size,
· Share & Trends
· Includes Updated List of tables & figures
· Updated Report Includes Top Market Players with their Business Strategies,
· Sales Volume, and Revenue Analysis
· Introspective Market Research Methodology
About us:
Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assisting our clients grow and have a successful impact on the market. Our team at IMR is ready to assist our clients flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, specialized in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyze extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.
Contact us:
Introspective Market Research
3001 S King Drive,
Chicago, Illinois
60616 USA
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek